文献速递糖尿病

非奈利酮在慢性肾脏病合并2型糖尿病患者中按钠-葡萄糖协同转运蛋白2抑制剂治疗分层:FIDELITY分析

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
PubMed 文献 · Diabetes Care · 2022-01-01

FIDELITY分析预设汇总FIDELIO-DKD和FIGARO-DKD两项3期研究,评估非奈利酮在合并慢性肾脏病(CKD)的2型糖尿病患者中按钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)使用情况分层的疗效。共纳入13,026例患者,基线使用SGLT2i者877例(6.7%),试验期间起始者1,113例(8.5%)。非奈利酮对心血管和肾脏复合终点的获益与SGLT2i使用无关(交互作用P值分别为0.46和0.29)。

要点

  • 非奈利酮降低心血管复合终点风险:未用SGLT2i者HR 0.87,用SGLT2i者HR 0.67。
  • 非奈利酮降低肾脏复合终点风险:未用SGLT2i者HR 0.80,用SGLT2i者HR 0.42。
  • 基线SGLT2i使用不影响非奈利酮的心肾获益(交互作用P=0.46和0.29)。

核心结论

  • 在合并CKD的2型糖尿病患者中,无论是否使用SGLT2i,非奈利酮相较安慰剂均可观察到心肾结局获益。

研究设计与样本

  • FIDELIO-DKD和FIGARO-DKD两项3期研究的预设汇总分析,共纳入13,026例2型糖尿病合并CKD患者。

主要发现

  • 心血管复合终点:未用SGLT2i者HR 0.87(95%CI 0.79-0.96),用SGLT2i者HR 0.67(95%CI 0.42-1.07)。
  • 肾脏复合终点:未用SGLT2i者HR 0.80(95%CI 0.69-0.92),用SGLT2i者HR 0.42(95%CI 0.16-1.08)。
  • 基线SGLT2i使用对心血管复合终点的交互作用P=0.46,对肾脏复合终点的交互作用P=0.29。

关键数值与推荐

  • 入选标准:2型糖尿病,尿白蛋白/肌酐比值(UACR)≥30至≤5,000 mg/g,估算肾小球滤过率(eGFR)≥25 mL/min/1.73 m2。
  • 随机分配至非奈利酮或安慰剂组,试验期间允许随时使用SGLT2i。
  • 复合终点定义:心血管复合终点包括心血管死亡、非致死性心肌梗死、非致死性卒中或心力衰竭住院;肾脏复合终点包括肾衰竭、eGFR持续下降≥57%或肾脏死亡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Finerenone reduced the risk of kidney and cardiovascular events in people with chronic kidney disease (CKD) and type 2 diabetes in the FIDELIO-DKD and FIGARO-DKD phase 3 studies. Effects of finerenone on outcomes in patients taking sodium-glucose cotransporter 2 inhibitors (SGLT2is) were evaluated in a prespecified pooled analysis of these studies. RESEARCH DESIGN AND METHODS: Patients with type 2 diabetes and urine albumin-to-creatinine ratio (UACR) ≥30 to ≤5,000 mg/g and estimated glomerular filtration rate (eGFR) ≥25 mL/min/1.73 m2 were randomly assigned to finerenone or placebo; SGLT2is were permitted at any time. Outcomes included cardiovascular composite (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure) and kidney composite (kidney failure, sustained ≥57% eGFR decline, or renal death) end points, changes in UACR and eGFR, and safety outcomes. RESULTS: Among 13,026 patients, 877 (6.7%) received an SGLT2i at baseline and 1,113 (8.5%) initiated one during the trial. For the cardiovascular composite, the hazard ratios (HRs) were 0.87 (95% CI 0.79-0.96) without SGLT2i and 0.67 (95% CI 0.42-1.07) with SGLT2i. For the kidney composite, the HRs were 0.80 (95% CI 0.69-0.92) without SGLT2i and 0.42 (95% CI 0.16-1.08) with SGLT2i. Baseline SGLT2i use did not affect risk reduction for the cardiovascular or kidney composites with finerenone (Pinteraction = 0.46 and 0.29, respectively); neither did SGLT2i use concomitant with study treatment. CONCLUSIONS: Benefits of finerenone compared with placebo on cardiorenal outcomes in patients with CKD and type 2 diabetes were observed irrespective of SGLT2i use.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Rossing P, Anker SD, Filippatos G, et al. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis. Diabetes Care. 2022. PMID: 35972218. doi:10.2337/dc22-0294

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。